Natera, Inc.
About Natera, Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $2.3B
- Net income
- -$208.2M
- Total assets
- $2.4B
- Market cap
- $30.8B
- Operating margin
- -13.4%
- Net margin
- -9.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.3B
- Operating expenses
- $2.6B
- Operating income
- -$309.9M
- Income tax
- -$59.9M
- Net income
- -$208.2M
- EPS (basic)
- $-1.52
- EPS (diluted)
- $-1.52
Balance sheet
- Total assets
- $2.4B
- Current assets
- $1.5B
- Total liabilities
- $685.9M
- Current liabilities
- $441.2M
- Shareholders’ equity
- $1.7B
Cash flow
- Operating cash flow
- $215.3M
- Investing cash flow
- -$132.2M
- Financing cash flow
- $47.5M
- Net cash flow
- $130.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $30.8B
- EPS (diluted)
- $-1.52
- Shares outstanding
- 144.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 2, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $208.2M in FY2025.
- Revenue grew 269% from FY2021 to FY2025.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Natera, Inc..
Write a review
News about Natera, Inc.
News & sentiment via Polygon.io
